军事知识服务平台
肿瘤的质子重离子放疗历史、现状和前景
History,current status and prospects of proton and heavy ion radiotherapy for tumors
摘要 质子和重离子放疗从发现这些离子射线至今已有1个多世纪的历史.质子和重离子射线在放射线物理剂量分布上比X线具有明显的优势.在进入介质后,在某个深度射线的能量骤然释放,形成1个高剂量区,然后剂量骤然下降.这个剂量分布特征被命名为"Bragg峰"现象.所以质子和重离子射线能较好地保护肿瘤周围正常组织.质子射线的相对生物学效应(relative biological effectiveness,RBE)比X线稍强,是X线的1.1~1.2倍.目前重离子射线中用于临床放疗的主要是碳离子.碳离子射线具有更强的肿瘤杀灭效应,RBE是X线的2~3倍,特别是对抗拒X线放疗的肿瘤(如乏氧肿瘤细胞)有更强的杀伤效应,其氧增强比(oxygen enhancement ratio,OER)是2左右,低于X线的3左右.全球正在运营的质子中心有128个,重离子中心有17个.到2024年全球治疗肿瘤患者数:质子超35万例,重离子超5万例.上海市质子重离子医院/复旦大学附属肿瘤医院质子重离子中心是中国第1个质子重离子放疗中心,于2015年5月开始正式运行.在过去的11年中,从零开始建立了质子碳离子放疗技术,对质子重离子放疗设备进行了部分技术改进.建立了各种肿瘤质子碳离子放疗的临床技术规范.到2026年5月,累计治疗患者9 317例,用碳离子或X线/质子射线加碳离子射线加量治疗的患者数占全部患者的75%.临床治疗结果显示,在放疗后复发的鼻咽癌、脑胶质母细胞瘤、不能手术的局部晚期胰腺癌中,碳离子放疗的效果优于X线放疗.在早期非小细胞肺癌、局部晚期非小细胞肺癌、原发性肝癌和局限期前列腺癌中,碳离子放疗的效果与X线放疗相当,但放疗相关不良反应明显小于X线放疗.质子放疗设备的价格和运营成本比较高,短期内质子放疗还不可能取代X线放疗,但随着放疗设备价格的下降,质子放疗将是中国今后放疗发展的主要方向.碳离子放疗是一个正在发展中的技术,目前还没有达到完全成熟的地步,在放射生物学和临床应用方面还有待进一步探索,但是碳离子放疗在临床肿瘤放疗中已经显示出明显优于X线放疗的疗效,比质子放疗也更具放射生物学方面的优势,所以碳离子和其他重离子射线是肿瘤放疗更有前景的一个发展方向.但由于投入巨大,目前只能在少数大医院开展,在短期内不可能成为肿瘤放疗发展的主流.
Abstract:
Proton and heavy ions were discovered a century ago.Compared with conventional X-ray beams,proton and heavy ion beams exhibit unique superiorities in radiophysical dose distribution.Upon penetration into biological media,these beams release energy abruptly at a specific depth to form a very concentrated high-dose region,followed by a rapid dose drop-off.This distinctive dose distribution characteristic was defined as the"Bragg peak"phenomenon,which enables proton and heavy ion beams to effectively spare peritumoral normal tissues.Proton beams possess slightly higher radiobiological effectiveness than X-rays,with a relative biological effectiveness(RBE)value of 1.1-1.2.Currently,carbon ion beam is the predominant heavy ion beam adopted in clinical radiotherapy.Carbon ion beam exerts a powerful tumor-killing capacity with an RBE of 2.0-3.0.Notably,carbon ion beam demonstrates a prominent tumor eradication effect against X-ray-resistant tumors,particularly hypoxic tumor cells.The oxygen enhancement ratio(OER)of carbon ion beam is approximately 2,lower than the OER of 3 in conventional X-rays.Globally,there are 128 operational proton therapy centers and 17 heavy ion therapy centers.As of 2024,more than 350 000 patients worldwide have been treated by proton radiotherapy,and over 50 000 patients by heavy ion radiotherapy.The Shanghai Proton and Heavy Ion Center/Proton and Heavy Ion Center,Fudan University Shanghai Cancer Center is the first center of this kind in China.It was officially launched for clinical practice in May 2015.Over the past 11 years,the center has established proton and carbon ion beam radiotherapy techniques and the standardized operating procedures for a variety of tumors.By May 2026,the center had treated a cumulative total of 9 317 patients,among whom 75%received carbon ion beam or carbon ion beam boost irradiation combined with X-ray or proton radiotherapy.Clinical outcomes have shown that carbon ion beam radiotherapy yielded significantly better efficacy than X-ray radiotherapy in the following cancers:recurrent nasopharyngeal carcinoma,glioblastoma and unresectable locally advanced pancreatic cancer.For early-stage and locally advanced non-small cell lung cancers,primary liver cancers,and localized prostate carcinoma,carbon ion beam radiotherapy achieved therapeutic efficacy equivalent to X-ray radiotherapy,but with substantially fewer radiation-related adverse events.Because of high capital investment,proton radiotherapy cannot replace conventional X-ray radiotherapy in the short term.However,with the gradual reduction in facility costs,proton radiotherapy will become a main modality for radiotherapy in China in the near future.Moreover,carbon ion beam radiotherapy has superior clinical efficacy over both X-ray and proton radiotherapy,and is considered a promising modality for the future,but due to the enormous capital investment requirements,carbon ion beam radiotherapy can only be carried out in a small number of tertiary hospitals,and will not become the mainstream radiotherapy modality in the near future.
刊 名 中国癌症杂志 ISTICPKU
年,卷(期): 2026, 36(9)
分类号: R730.55
机标分类号: R714.252 TK018 S7-932
在线出版日期: 2026年11月2日